BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34453189)

  • 1. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
    Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
    Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAMTS-13-VWF axis in sickle cell disease patients.
    Ladeira VS; Barbosa AR; Oliveira MM; Ferreira LGR; de Oliveira Júnior WV; de Oliveira Renó C; Reis EA; Chaves DG; Dusse LMS; Dos Santos HL; de Barros Pinheiro M; Rios DRA
    Ann Hematol; 2021 Feb; 100(2):375-382. PubMed ID: 33404693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD163 levels in children with sickle cell disease.
    Moller HJ; Nielsen MJ; Bartram J; Dick MC; Height SE; Moestrup SK; Rees DC
    Br J Haematol; 2011 Apr; 153(1):105-10. PubMed ID: 21332709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAMTS13 activity in sickle cell disease.
    Schnog JJ; Kremer Hovinga JA; Krieg S; Akin S; Lämmle B; Brandjes DP; Mac Gillavry MR; Muskiet FD; Duits AJ;
    Am J Hematol; 2006 Jul; 81(7):492-8. PubMed ID: 16755558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates.
    Novelli EM; Kato GJ; Ragni MV; Zhang Y; Hildesheim ME; Nouraie M; Barge S; Meyer MP; Hassett AC; Gordeuk VR; Gladwin MT; Isenberg JS
    Am J Hematol; 2012 Mar; 87(3):326-30. PubMed ID: 22318901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
    Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
    World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial Nitric Oxide Synthase (eNOS) Gene Polymorphisms and Markers of Hemolysis, Inflammation and Endothelial Dysfunction in Brazilian Sickle Cell Anemia Patients.
    Chenou F; Albuquerque DM; Leonardo DP; Domingos IF; Bezerra MAC; Araújo AS; Blotta MHSL; Costa FF; Sonati MF; Paula EV; Santos MNN
    Biochem Genet; 2020 Aug; 58(4):580-594. PubMed ID: 32277314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of endothelial dysfunction differ between subphenotypes in children with sickle cell disease.
    van der Land V; Peters M; Biemond BJ; Heijboer H; Harteveld CL; Fijnvandraat K
    Thromb Res; 2013; 132(6):712-7. PubMed ID: 24182550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the level of von willebrand factor and ADAMTS13 in sickle cell anaemia patients in steady state.
    Kingsley A; Ofonime E; Enobong U; Iquo I
    Niger J Clin Pract; 2022 Sep; 25(9):1393-1397. PubMed ID: 36149195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VWF-ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion.
    Fogarty H; Ahmad A; Atiq F; Doherty D; Ward S; Karampini E; Rehill A; Leon G; Byrne C; Geoghegan R; Conroy H; Byrne M; Budde U; Schneppenheim S; Sheehan C; Ngwenya N; Baker RI; Preston RJS; Tuohy E; McMahon C; O'Donnell JS
    Blood Adv; 2023 Nov; 7(22):6974-6989. PubMed ID: 37773926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.
    Lanaro C; Franco-Penteado CF; Albuqueque DM; Saad ST; Conran N; Costa FF
    J Leukoc Biol; 2009 Feb; 85(2):235-42. PubMed ID: 19004988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
    Sins JWR; Schimmel M; Luken BM; Nur E; Zeerleder SS; van Tuijn CFJ; Brandjes DPM; Kopatz WF; Urbanus RT; Meijers JCM; Biemond BJ; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1392-1402. PubMed ID: 28457019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.
    Chen J; Hobbs WE; Le J; Lenting PJ; de Groot PG; López JA
    Blood; 2011 Mar; 117(13):3680-3. PubMed ID: 21300978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
    Saleh AW; Hillen HF; Duits AJ
    Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered von Willebrand Factor and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension.
    Islek A; Ilhan D; Ozturk N; Guven B; Sag E
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e951-e956. PubMed ID: 33369998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined hydroxyurea and ET
    Taylor C; Kasztan M; Tao B; Pollock JS; Pollock DM
    Acta Physiol (Oxf); 2019 Feb; 225(2):e13178. PubMed ID: 30144292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of Thrombospondin 1 to von Willebrand Factor and ADAMTS-13 in Sickle Cell Disease Patients of Arab Ethnicity.
    Al-Awadhi A; Adekile A; Marouf R
    Acta Haematol; 2021; 144(2):182-189. PubMed ID: 32987383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease.
    Belcher JD; Chen C; Nguyen J; Milbauer L; Abdulla F; Alayash AI; Smith A; Nath KA; Hebbel RP; Vercellotti GM
    Blood; 2014 Jan; 123(3):377-90. PubMed ID: 24277079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased von Willebrand factor ristocetin cofactor activity and increased ADAMTS13 antigen increase postoperative drainage after coronary artery bypass grafting.
    Mazur P; Plicner D; Zdziarska J; Sadowski J; Undas A
    Eur J Cardiothorac Surg; 2014 Feb; 45(2):e26-32. PubMed ID: 24351199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of ADAMTS13-independent VWF regulation in sickle cell disease.
    Hunt RC; Katneni U; Yalamanoglu A; Indig FE; Ibla JC; Kimchi-Sarfaty C
    J Thromb Haemost; 2022 Sep; 20(9):2098-2108. PubMed ID: 35753044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.